Combination Products: Regulatory Challenges and Successful Product Development

Combination Products: Regulatory Challenges and Successful Product Development

Volumn , Issue , 2008, Pages 1-241

  Gopalaswamy, Smita ^a   Gopalaswamy, Venky ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79551663545     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (65)

1. Early development considerations for innovative combination products. Guidance for industry and FDA staff, Offi ce of Combination Products, 2006.
2. Final rule on the defi nition of primary mode of action of a combination product. Federal Register 49848, August 25, 2005.
3. Guidance for industry and FDA current good manufacturing practice for combination products. Draft guidance, Offi ce of Combination Products, September 2004.
4. Innovative systems for delivery of drugs and biologics: scientifi c, clinical and regulatory challenges. FDA workshop. Bethesda, Maryland, July 8, 2003.
5. Interface with other directives-medical devices/medicinal products. European Commission, 2001. http://ec.europa.eu/enterprise/medical_devices/meddev/2_1307- 2001.pdf
6. Kramer, Mark D. Combination products: challenges and progress. Regulatory Affairs Focus, pp. 30-35, August, 2005.
7. Harry, Mikel and Schroeder, Richard. Six Sigma, The Breakthrough Management Strategy. New York: Doubleday, 2000.
8. Justiniano, Jose and Gopalaswamy, Venky. Practical Design Control Implementation for Medical Devices. InterPharm/CRC Press, 2002.
9. Justiniano, Jose and Gopalaswamy, Venky. Six Sigma for Medical Device Design. CRC Press, 2005.
10. Application user fees for combination products; availability. Draft guidance for industry and FDA staff. Federal Register 69(87):57942-57943, 2004.
11. Assignment of agency component for review of premarket applications. Final rule, FDA. Federal Register 68:37075-37077, 2003.
12. Combination products: timeliness of premarket reviews: dispute resolution guidance. Draft guidance for industry, FDA, 2004. www.fda.gov/oc/combination/dispute. html.
13. Cramer, Chris and Rastogi, Sharad. Drug and device combinations, combination medical products: capitalizing on convergence. Medical Device & Diagnostic Industry, January 2007.
14. Current good manufacturing practice for combination products. Draft guidance for industry, FDA, 2004. www.fda.gov/oc/combination/OCLove1dft.html.
15. Definition of primary mode of action of a combination product. Proposed rule, FDA. Federal Register 69(89):25527-25533, 2004.
16. DiMasi, Joseph, et al. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22: 151-185, 2003.
17. Early collaboration meetings under the FDA Modernization Act: http://www.fda. gov/cdrh/ode/guidance/310.html
18. Early development considerations for innovative combination products. Guidance for industry and FDA staff, Office of Combination Products, September 2006.
19. Innovative systems for delivery of drugs and biologics: scientific, clinical and regulatory challenges. FDA workshop. Bethesda, Maryland, July 8, 2003.
20. Federal Food, Drug, and Cosmetic Act, Section 503(g), as amended: http://www.fda. gov/opacom/laws/fdcact/fdctoc.htm
21. Federal Food, Drug, and Cosmetic Act, Section 563, as amended: http://www.fda.gov/ opacom/laws/fdcact/fdctoc.htm
22. Fox, David M., and Shapiro, Jeffrey K. Combination products: how to develop the optimal strategic path for approval. FDA News, 2005.
23. Gross, Ames. Growing opportunities in the Indian medical device market. Medical Device & Diagnostic Industry, May 1995.
24. Gross, Ames and Loh, Nancy. Medical device regulatory update: China and Japan. Medical Device & Diagnostic Industry, October 2006.
25. Gross, Ames and Weintraub, Rachel. Regulatory updates for drugs, devices & IVDs in Asia. Regulatory Affairs Focus, May 2005.
26. Jepson, Gordon. The business impact of noncompliance (consequences of noncompliance in Canada: regulatory enforcement agencies, powers and practices). Regulatory Affairs Focus, January 2007.
27. Kader, Victoria and Priestley, Duaine A. India's medical device market is becoming too big to ignore. Medical Device & Diagnostic Industry, April 1997.
28. Leichter, Lee H. Pathways and strategies for combination products in the EU. Regulatory Affairs Focus, September 2003.
29. Patel, Neesha. Implications of medical device regulations. Express Health Care Management, September 2006.
30. Portnoy, Stuart and Koepke, Steven. Regulatory strategy: drug testing of combination products. Medical Device & Diagnostic Industry, June 2005.
31. Stephens, Robin N. Bringing drug-eluted stents to Europe. Regulatory Affairs Focus, pp. 57-59, February/March 2004.
32. Gibbs, Jeffrey, Phelps, Hyman and McNamara, P.C. State of the union: drug-device combinations. Medical Device & Diagnostic Industry, November 2006.
33. Kramer, Mark D. Combination products: challenges and progress. Regulatory Affairs Focus, pp. 30-35, August, 2005.
34. Mannix, Daniel G. Combination products. Regulatory Affairs Focus, September 2006.
35. Michalik, Robert J. Regulation of combination products: marmonization or unifi cation? Regulatory Affairs Focus, September 2006.
36. Swain, Erik. Extra effort: packaging for combination products. Medical Device & Diagnostic Industry 27, pp. 98-106, 2005.
37. Butschli, Jim. Combination products challenge packaging. Packaging World, June 2006.
38. Guide to inspections of Microbiological pharmaceutical quality control laboratories. FDA, July 1993.
39. Masefi J., Brinston, R. Radiation sterilization of advanced drug-device combination products. Medical Device Technology, March/April 2007.
40. Matlis, Daniel R. Making life-sciences from life. White paper prepared for CAMSTAR, June 2007.
41. Triolo, Phil. Coated Combination Products: Regulation and Technology. Medical Device & Diagnostic Industry, January 2005.
42. Boam, Ashley B. Drug-eluting stents: an FDA case study. Regulatory Affairs Focus, pp. 18-23, November 2003.
43. Broderick, Julie N. Brave new world: EU combination products regulation. Regulatory Affairs Focus, September 2006.
44. ISO 10993-1: Biological Evaluation of Medical Devices-Part 1: Evaluation and Testing, 2nd ed. International Organization for Standardization, 1997.
45. Kramer, Mark D. Combination products: challenges and progress. Regulatory Affairs Focus, pp. 30-35, August, 2005.
46. Patel, Subhash. Combination products: puzzles of regulations. Regulatory Affairs Focus, September 2006.
47. Pitkin, Zorina. Regulation of biologic/device combination products. Regulatory Affairs Focus, June 2000.
48. Sall, Barry S., Lassoff, Peter and Babbitt, Bruce. Getting started with a combination product: Part I, Overcoming the regulatory challenges in this ever-expanding fi eld yields rewards. Medical Device & Diagnostic Industry, March 2003.
49. Keramidas, Sherry. The challenge of combination products and beyond, Regulatory Affairs Focus, September 2006.
50. Klassen, Dan G. Post marketing/GMPs, after licensure no time to relax. Regulatory Affairs Focus, April 2006.
51. Leichter, Lee. Medical device combination products. Regulatory Affairs Focus, February 2001.
52. Medical Device Innovation Initiative. FDA, CDRH, May 2006.
53. Current good manufacturing practice for combination products. Federal Register, April 24, 2006.
54. FDA Compliance Program Guidance Manual. Program 7346.843: Post approval audit inspections. September 15, 1994.
55. FDA Compliance Policy Guide 7150.09, Section 120.100, Fraud, Untrue Statements of material facts, bribery, and illegal gratuities. FDA, July 1, 1991.
56. Human Drug CGMP Notes, Volume 2, Number 1. FDA, CDER, March 1994.
57. Michor, Salma. How to avoid non-compliance. Regulatory Affairs Focus, pp. 10-13 January 2007.
58. Offi ce of the inspector general's compliance program guidance for pharmaceutical manufacturers. Federal Register, May 5, 2003.
59. Points to consider for internal reviews and corrective action operating plans. FDA, June 1991.
60. Portnoy, Stuart and Koepke, Steven. Regulatory strategy: pre-clinical testing of combination product. Medical Device & Diagnostic Industry, May 2005
61. Richter, Steven. Combination products: navigating two FDA quality systems. Microtest, white paper, January 2007.
62. Sullivan, John and Elbaek, Henrik. Combination products face additional regulatory hurdles abroad. Medical Product Outsourcing, April 2007.
63. Swain, Eric. Extra effort: packaging for combination products. Medical Device & Diagnostic Industry, January 2005.
64. Triolo, Phil. Coated combination products: regulation and technology. Medical Device & Diagnostic Industry, March 2005.
65. Viscogliosi, Marc R. Building a new model for spine care: when the dust settles, technologies and procedures for treating spine conditions will look very different. Medical Device Link, May 2007.